1. Show article details.

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Inovio Pharmaceuticals (INO) Investors with Significant Losses to Contact its Attorneys: Important Application Deadline Approaching

    GlobeNewswire – 8:24 PM ET 04/06/2020

    Hagens Berman urges investors in Inovio Pharmaceuticals, Inc. (INO) who have suffered significant losses to submit their losses now.

  2. Show article details.

    Inovio Pharmaceuticals plans first dosing of patients in trial of DNA COVID-19 vaccine candidate on Monday

    MarketWatch – 10:24 AM ET 04/06/2020

    Inovio Pharmaceuticals Inc. (INO) is planning the first dosing of patients in a Phase 1 trial of its DNA vaccine candidate to treat COVID-19 on Monday, the company said in a statement. The vaccine, named INO-4800, has shown promising response in preclinical animal studies, the company said. The trial will involve up to 40 healthy volunteers at two trial locations in Phladelphia and Kansas City.

  3. Show article details.

    BRIEF-Inovio Initiates Phase 1 Clinical Trial Of Its Covid-19 Vaccine

    Reuters – 8:52 AM ET 04/06/2020

    Inovio Pharmaceuticals Inc (INO): * INOVIO INITIATES PHASE 1 CLINICAL TRIAL OF ITS COVID-19 VACCINE AND PLANS FIRST DOSE TODAY. * INOVIO - U.S. FDA ACCEPTED CO'S IND APPLICATION FOR INO-4800, ITS DNA VACCINE CANDIDATE DESIGNED TO PREVENT COVID-19 INFECTION. * Inovio Pharmaceuticals Inc (INO) - PHASE 1 STUDY OF INO-4800 WILL ENROLL UP TO 40 HEALTHY ADULT VOLUNTEERS.

  4. Inovio plans first dosing of patients in trial of DNA COVID-19 vaccine candiate on Monday

    MarketWatch – 8:34 AM ET 04/06/2020
  5. Show article details.

    INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today

    PR Newswire – 8:30 AM ET 04/06/2020

    PLYMOUTH MEETING, Pa., April 6, 2020  INOVIO Pharmaceuticals, Inc. (INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, paving the way for Phase 1 clinical testing of INO-4800 in healthy volunteers beginning this week.

  6. Show article details.

    Kessler Topaz Meltzer & Check, LLP Reminds Inovio Pharmaceuticals, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit

    GlobeNewswire – 10:18 AM ET 04/04/2020

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds Inovio Pharmaceuticals, Inc. (INO) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Inovio on behalf of those who purchased or otherwise acquired Inovio common stock between February 14, 2020 and March 9, 2020, inclusive.

  7. Show article details.

    BRIEF-Inovio Pharmaceuticals Filed Prospectus Supplement Pursuant To Sales Agreement For Offering Of Up To $150 Million

    Reuters – 6:30 PM ET 04/03/2020

    Inovio Pharmaceuticals Inc (INO): * INOVIO PHARMACEUTICALS (INO)- FILED PROSPECTUS SUPPLEMENT PURSUANT TO SALES AGREEMENT FOR OFFERING OF UP TO $150 MILLION.

  8. Show article details.

    BRIEF-Inovio Pharmaceuticals Says Entered Into An At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

    Reuters – 5:29 PM ET 04/03/2020

    Inovio Pharmaceuticals Inc (INO): * Inovio Pharmaceuticals Inc (INO) - ENTERED INTO AN AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & CO. * INOVIO PHARMACEUTICALS (INO)- MAY OFFER AND SELL, SHARES OF COMMON STOCK, PAR VALUE $0.001PER SHARE THROUGH STIFEL Source: https://bit.ly/2yvb03j Further company coverage:

  9. Show article details.

    Insurers fret as company bosses face coronavirus legal claims

    Reuters – 11:09 AM ET 04/01/2020

    Insurers are increasingly worried about shareholders, employees or customers bringing coronavirus-related claims against company executives and are considering excluding the virus from policies which protect the bosses, industry sources say.

  10. Show article details.

    BRIEF-Inovio Interim Results Of An Open-Label Phase 2 Trial Of Vgx-3100 Show Efficacy Against Hpv-Associated Vulvar Dysplasia

    Reuters – 9:11 AM ET 03/30/2020

    Inovio Pharmaceuticals Inc (INO): * INOVIO INTERIM RESULTS OF AN OPEN-LABEL PHASE 2 TRIAL OF VGX-3100 SHOW EFFICACY AGAINST HPV-ASSOCIATED VULVAR DYSPLASIA. * INOVIO PHARMACEUTICALS (INO) - REPORTING INTERIM DATA ON 10 SUBJECTS WHO COMPLETED PRIMARY ENDPOINT EVALUATION AT SIX MONTHS FOLLOWING TREATMENT WITH VGX-3100.

  11. Show article details.

    INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia

    PR Newswire – 9:00 AM ET 03/30/2020

    PLYMOUTH MEETING, Pa., March 30, 2020  INOVIO Pharmaceuticals, Inc. (INO) today reported interim results from an open-label Phase 2 trial designed to evaluate the safety and efficacy of VGX-3100 in women with vulvar dysplasia, also known as high grade squamous intraepithelial lesion, a precancerous condition caused by high-risk human papillomavirus types 16 and/or 18.

  12. Show article details.

    BRIEF-Inovio Reports Positive Interim Phase 2 VGX-3100 Results In Patients With HPV-Associated Anal Dysplasia

    Reuters – 9:05 AM ET 03/26/2020

    Inovio Pharmaceuticals Inc (INO): * INOVIO REPORTS POSITIVE INTERIM PHASE 2 VGX-3100 RESULTS IN PATIENTS WITH HPV-ASSOCIATED ANAL DYSPLASIA. * INOVIO- VGX-3100 DNA CLEARED HIGH-RISK HPV 16/18-ASSOCIATED PRECANCEROUS LESIONS IN 50% PATIENTS, REDUCED NUMBER OF LESIONS IN 75% PATIENTS Source text for Eikon: Further company coverage:

  13. Show article details.

    INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia

    PR Newswire – 9:00 AM ET 03/26/2020

    PLYMOUTH MEETING, Pa., March 26, 2020  INOVIO Pharmaceuticals, Inc. (INO) today announced positive interim results from an open-label, Phase 2 study showing its lead DNA medicine candidate VGX-3100 to be safe and effective in treating men and women with anal dysplasia, also known as high grade squamous intraepithelial lesion, a precancerous condition caused by high-risk human papillomavirus types 16/18.

  14. Show article details.

    Notice of Lead Plaintiff Deadline for Shareholders in the Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit

    Business Wire – 9:00 AM ET 03/26/2020

    Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (INO) common stock between February 14, 2020 and March 9, 2020.

  15. Show article details.

    RM LAW Announces Class Action Lawsuit Against Inovio Pharmaceuticals, Inc.

    PR Newswire – 3:45 PM ET 03/24/2020

    BERWYN, Pa., March 24, 2020  RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Inovio Pharmaceuticals, Inc. (INO)   securities during the period from February 14, 2020 through March 9, 2020, inclusive. Inovio shareholders may, no later than May 11, 2020, move the Court for appointment as a lead plaintiff of the Class.

  16. Show article details.

    Inovio and Ology Bioservices awarded $11.9 million contract from DoD to work on COVID-19 vaccine

    MarketWatch – 8:39 AM ET 03/24/2020

    Inovio Pharmaceuticals Inc. (INO) and privately held Ology Bioservices Inc. said Tuesday they have been awarded an$ 11.9 million contract by the Department of Defense to work on Inovio's DNA technology to manufactuve vaccines, including Inovio's current COVID-19 candidate. Plymouth Meeting, Pa.-based Inovio has already won grants from Coalition for Epidemic Preparedness Innovations, a global organization based in Oslo, and the Gates Foundation to fund the development of the...

  17. Show article details.

    BRIEF-Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Mlon Department Of Defense Grant

    Reuters – 8:18 AM ET 03/24/2020

    Inovio Pharmaceuticals Inc (INO): * OLOGY BIOSERVICES, INOVIO PARTNER TO MANUFACTURE COVID-19 DNA VACCINE WITH $11.9 MILLION DEPARTMENT OF DEFENSE GRANT. * INOVIO PHARMA - DEPARTMENT OF DEFENSE AWARDED OLOGY BIOSERVICES WITH $11.9 MILLION CONTRACT TO WORK WITH INOVIO ON DNA TECHNOLOGY TRANSFER TO MANUFACTURE DNA VACCINES.

  18. Show article details.

    Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant

    PR Newswire – 8:00 AM ET 03/24/2020

    PLYMOUTH MEETING, Pa. and ALACHUA, Fla. Under this program, Ology Bioservices will work with Inovio Pharmaceuticals (INO) to manufacture Inovio's DNA vaccine for prevention of infection with the COVID-19 virus.

  19. Show article details.

    Kaskela Law LLC Announces Deadline in Shareholder Class Action Lawsuit Filed Against Inovio Pharmaceuticals, Inc. (INO) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    GlobeNewswire – 8:00 AM ET 03/24/2020

    Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (INO) on behalf of investors who purchased shares of the Company’s stock between February 14, 2020 and March 9, 2020, inclusive.

  20. Show article details.

    Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant

    Business Wire – 8:00 AM ET 03/24/2020

    Ology Bioservices Inc., a biologics contract development and manufacturing organization, and Inovio Pharmaceuticals Inc. (INO), developing DNA medicines for infectious diseases and cancer, announced today that the Department of Defense has awarded Ology Bioservices with a contract valued at $11.9 million to work with Inovio on DNA technology transfer to rapidly manufacture DNA vaccines.

Page:

Today's and Upcoming Events

  • May
    11

    INO to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Mar
    12

    INO announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.